Treatment Strategies in ESR1-mut ER+/HER2- Breast Cancer: Practical Insights for Optimal Outcomes

Tiffany A. Traina, MD, FASCO; Melissa Rikal, MSN, FNP-BC, AOCNP, and Marissa Marti-Smith, DNP, APRN, AGNP-C, AOCNP discuss how emerging treatment strategies and molecular profiling are transforming the management of metastatic hormone receptor-positive, HER2-negative breast cancer, with a specific focus on ESR one mutations and the potential of new targeted therapies like L-acstrin.